ResearchSafe

Cerebrolysin (Cerebrolysin (Brain-Derived Peptide Preparation))

Category: Cognitive & Nootropic. Status: Investigational.

A multi-peptide preparation from porcine brain containing neurotrophic factors. Approved in 40+ countries for stroke and dementia, providing a cocktail of low-MW neuropeptides.

How it works

Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis.

Key facts

  • Molecular weight: <10,000 Da (peptide fraction)
  • Half-life: 4-6 hours
  • Bioavailability: High (IM/IV)
  • Storage: Refrigerated 2-8°C. Amber ampoules.

Dosing overview

  • Typical dose: 5-30 mL
  • Frequency: Daily for 10-20 days
  • Duration: 10-20 day courses, 2-4x yearly
  • Route: Intramuscular or IV

Reported benefits

  • Neurotrophic support
  • Stroke recovery
  • Memory improvement
  • Neuroprotection
  • Synaptic plasticity
  • Approved in 40+ countries

Possible side effects

  • Injection pain
  • Dizziness
  • Headache
  • Agitation
  • Allergic reaction (porcine)

Research

  • Cerebrolysin in acute ischemic stroke (CASTA) (2020): 30mL daily for 10 days improved neurological recovery at 90 days in moderate-severe stroke.
  • Cerebrolysin in Alzheimer disease (2021): Six-month courses stabilized ADAS-Cog scores vs progressive decline in placebo over 28 weeks.

Compare Cerebrolysin

Community discussions about Cerebrolysin

Research and educational reference only. Not medical advice.